Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

Learn more about CME

Antiplatelet and Anticoagulant Drugs for Elective Percutaneous Coronary Intervention (PCI)

MoreVert
AddCircleOutlineFollow
ShareShare
AddCircleOutlineFollow
Follow
ShareShare
Share

You must be a subscriber to see the full topic content.

  • KeyboardArrowRight

    Overview and Recommendations

    • Background

    • Management

  • Related Summaries

  • Overview

  • KeyboardArrowRight

    Recommendations From Professional Organizations

    • American College of Cardiology (ACC)/American Heart Association (AHA)

    • European Society of Cardiology (ESC)

    • American College of Cardiology Foundation/American Heart Association/Society for Cardiovascular Angiography and Interventions (ACCF/AHA/SCAI)

    • American College of Chest Physicians (ACCP)

    • Recommendations for patients with atrial fibrillation

  • Aspirin

  • KeyboardArrowRight

    P2Y12 Inhibitors and Dual Antiplatelet Therapy (DAPT)

    • General information

    • Duration of Dual Antiplatelet Therapy (DAPT)

    • KeyboardArrowRight

      Clopidogrel

      • Efficacy of clopidogrel

      • Loading dose for clopidogrel

      • Daily dose for clopidogrel

      • Duration of clopidogrel

      • Testing for clopidogrel responsiveness

    • Cangrelor

    • Ticagrelor

    • Other antiplatelet drugs

  • KeyboardArrowRight

    Glycoprotein IIb/IIIa Inhibitors

    • Class effects of glycoprotein IIb/IIIa blockers

    • Abciximab

    • Eptifibatide

    • Tirofiban

    • Xemilofiban

    • Comparisons of glycoprotein IIb/IIIa inhibitors

  • KeyboardArrowRight

    Anticoagulants

    • Unfractionated heparin

    • Enoxaparin

    • Bivalirudin

    • Other anticoagulant agents

  • KeyboardArrowRight

    Dual Therapies Compared to Triple Therapy

    • In patients with atrial fibrillation

  • Revascularization Before Noncardiac Surgery and Dual Antiplatelet therapy

  • Use in Chronic Kidney Disease

  • KeyboardArrowRight

    Quality Improvement

    • Physician Quality Reporting System Quality Measures

  • KeyboardArrowRight

    Guidelines and Resources

    • KeyboardArrowRight

      Guidelines

      • International guidelines

      • United States guidelines

      • Canadian guidelines

      • European guidelines

    • Review articles

  • KeyboardArrowRight

    References

    • General references used

    • Recommendation grading systems used

    • Synthesized Recommendation Grading System for DynaMed

    • DynaMed Editorial Process

    • Special acknowledgements

    • How to cite

Topic Editor
Pinak Shah MD
KeyboardArrowDown
Affiliations

Assistant Professor of Internal Medicine, Harvard Medical School; Massachusetts, United States

Recommendations Editor
Zbys Fedorowicz MSc, DPH, BDS, LDSRCS
KeyboardArrowDown
Affiliations

Director of Bahrain Branch of the United Kingdom Cochrane Center, The Cochrane Collaboration; Awali, Bahrain

Conflicts of Interest

Dr. Fedorowicz declares no relevant financial conflicts of interest.

Deputy Editor
Peter Oettgen MD
KeyboardArrowDown
Affiliations

Editor in Chief, DynaMed; Cardiologist, Beth Israel Deaconess Medical Center; Massachusetts, United States; Associate Professor of Medicine, Harvard Medical School; Massachusetts, United States

Conflicts of Interest

Dr. Oettgen declares no relevant financial conflicts of interest.

CheckCircle

top